Peer-influenced content. Sources you trust. No registration required. This is HCN.

ACP InternistIDSA Offers Guidance on Managing Drug Interactions with Nirmatrelvir/Ritonavir

The Infectious Diseases Society of America (IDSA) has issued guidance on managing drug interactions with nirmatrelvir/ritonavir (Paxlovid). Specifically, the IDSA recommends clinicians take six steps to minimize the risk of drug interactions for patients with COVID-19 who are eligible for nirmatrelvir/ritonavir.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form